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ABSTRACT 
Nutritional anaemia is frequently observed in India. Prevalence of anaemia in Indian children is 
59% (Hb<11gm/dl) but it’s higher among rural children. Iron deficiency is most common type 
nutritional deficiency anaemia in children. The nearest correlation of iron deficiency anemia 
(IDA) can be made with Pandu Roga in Ayurveda. The side effects of oral allopathic iron 
preparations are very common, therefore to get a better alternative, two Ayurvedic medicines, 
the Guda Haritaki and Punarnava Mandura, were subjected to a clinical trial among children 
suffering from IDA. Aim: Determine the role of Guda Haritaki and Punarnava Mandura in the 
management of Pandu roga w.s.r. to iron deficiency anaemia among children. Materials and 
Methods: The study was conducted on 35 children of IDA for a period of 6 weeks. Clinical 
features (Panduta, Daurbalya etc.) and hematological parameters (Hb gm %, sr. ferritin etc.) 
were documented before, during and after treatment. Statistical Analysis Used: Observations of 
the study were analyzed and findings were evaluated by using statistical methods Results: In 
the present study 58.82% improvement in Panduta was observed with Guda haritaki, 65% with 
Punarnava Mandura and 67 % when both drugs were given together. No adverse effect of the 
trial drug was observed during the study. Conclusions: The results suggest that Punarnava 
mandura along with Guda Haritaki is more effective in comparison to single use of either 
formulation in the management of IDA in children.  
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INTRODUCTION 
The clinical features like pallor, anorexia, 
irritability and pica etc clinically manifest Iron 
deficiency anaemia. Iron deficiency anaemia is 
affecting nearly 2 billion people globally i.e. around 
1/3 of the whole population [1].In India, iron 
deficiency is responsible in about 50% of anaemic 
cases. Adolescents constitute more than 20% of 
Indian population and more than 50% of them suffer 
from iron deficiency anemia[2]. NFHS 2015-16 
suggests that prevalence of anaemia in Indian 
children is 59% (Hb<11gm/dl) but it’s higher among 
rural children. Nutritional iron deficiency is the most 
common cause of anemia in India.[3] The features of 
iron deficiency anaemia are almost similar with that 
of Pandu Roga mentioned in Ayurvedic classics. The 
ancient system of medicine has described Pandu 
(disease of pallor) which includes various types of 
anaemia. IDA is a very common disease prevalent in 
the society and side effects of oral allopathic iron 
preparations are very frequently encountered.[4] 
There are about 200 preparations are quotated in 
various ayurvedic texts for management of Pandu 
Roga. With the aim that Ayurvedic medicines may be 
effective to manage childhood IDA without any side 
effects, the present study was carried out to study the 
efficacy of an Ayurvedic herbomineral compound 
Guda Haritaki and Punarnava Mandura with the 
application of modern parameters like hemoglobin 
conc., serum ferritin value and MCV, MCHC etc.  
AIMS AND OBJECTIVES 
Primary objective: To assess the clinical efficacy of 
Punarnava Mandura and Guda Haritaki in the 
management of iron deficiency anaemia among 
children. 
Secondary objective: To assess the clinical safety of 
Punarnava Mandura and Guda Haritaki in the 
patients of iron deficiency anaemia. 
Plan of Study 
Conceptual study: Ayurvedic and modern literature 
pertaining to iron deficiency anaemia was critically 
reviewed. 
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Clinical study: This was the main part of the present 
research work. A sample of 35 patients was assessed 
during the trial.  
The registered study subjects were randomly divided 
in three groups.  
Group A: 15 Patients – Guda Haritaki 500mg/kg/day, 
before meal (divided in two doses) 
Group B: 10 patients – Punarnava Mandura 500 mg 
twice a day, before meal  
Group C: 10 Patients – Each patient was managed as 
follows. 
1. Guda Haritaki 500mg/kg/day, before meal 
(divided in two doses) 
2. Punarnava Mandura 500 mg twice a day, before 
meal 
Protocol of Research 
1. Consent: A voluntary, signed, witnessed consent 
was obtained from the participants/ parents/ 
guardians prior to the clinical study. 
2. Selections of the patients: Patients were 
randomly selected from OPD and IPD of R.G.G. 
P.G. Ayurvedic College and Hospital Paprola 
district Kangra (H.P.) 
3. Diagnosis of patients: A detailed history was 
taken and complete physical examination, 
laboratory investigations were carried out based 
on both Ayurvedic as well as modern system of 
medicine to confirm the diagnosis of iron 
deficiency anaemia.  
Inclusion Criteria 
1. Children of either sex aged between 10-16 years. 
2. Children with iron deficiency anaemia having Hb 
levels between 7-11 gm%. 
3. Patients willing and able to participate for 6 
weeks duration. 
Exclusion Criteria 
1. Children having Hb levels < 7gm% or >11 gm%. 
2. Children suffering from major systemic illness 
necessitating long term drug treatment. 
3. Children having co- morbidities like tuberculosis, 
chronic urinary tract infection, bleeding 
disorders etc. 
4. History of hypersensitivity to any of the trial drug 
or their ingredients. 
5. Children who have participated in any other 
clinical trial during the past six months. 
6. Any other condition which the Principal 
investigator thinks may jeopardize the study. 
 Criteria for Withdrawal 
1. Patients non complaint to treatment regimen. 
2. Patient himself /herself wants to withdrawn from 
trial. 
3. Patients who will develop any other co-morbidity 
during trial period which require immediate 
pharmacological intervention. 
4. Adverse drug reaction to trial drug. 
Methods of Sampling 
 Direct sampling, double arm study 
(Randomized Clinical Trial) was followed. 
Selection of the Drug  
In the classical texts, many preparations have 
been mentioned for the treatment of Pandu roga, out 
of which for the present study as a trial drug a 
herbomineral compound "Punarnava Mandura"[5] 
and Guda Haritaki” [6] have been selected which is 
mentioned in the Ayurvedic classic Charaka Samhita 
and Sushruta Samhita-Panduroga chikitsadhyaya. 
Selection of Drug Form 
As quoted by Charakacharya that the drugs to 
be administered in Baala should have Madhura, 
Kashaya Rasa. After various pilot studies the Avaleha 
dosage form was found to be more acceptable and 
hence Avaleha form has been selected for the present 
study. 
Approval of Institutional Ethical Committee 
 Institutional Ethics committee’s approval was 
taken for the prospective, randomized parallel group 
clinical study. 
Procurement of the Drug 
 Guda Haritaki was prepared in the attached 
Charaka pharmacy of the institute. The trial drug 
Punarnava Mandura is prepared by K.L.E. Ayurveda 
Pharmacy, Upper Galli-Khasbag, Belgavi-4. All 
concerned drugs are taken in mentioned proportion 
in text and made in to Vati form of 250 mg each. 
Contents of the Trial Drugs 
Contents of Guda Haritaki and Punaranava 
Mandura are presented in Table 1 and Table no. 2 
respectively. 
Table 1: Ingredients of Guda Haritaki 
S.no.  Name  Botanical /English name  Family  Part used  
1  Haritaki  Terminalia chebula  Combretaceae  Pericarp  
2  Guda  Jaggerry  --  - 
3   Madhu   Honey  -  - 
 
Int. J. Ayur. Pharma Research, 2019;7(9):8-18 
     Available online at: http://ijapr.in  10 
Table 2: Ingredients of Punarnava Mandura 
Sr.No. Name Botanical name Family Part used 
1. Punarnava  Boerhaavia diffusa Linn. Nyctaginaceae Root 
2. Mustaka Cyperus rotundusLinn. Cyperaceae Rhizome 
3. Trivrita Operculina turpethum Linn. Convulvulaceae Root 
4. Vyosha Zingiber officinalis Roxb. Zingeberaceae Rhizome 
5. Vidanga Embelia ribes Burm.F. Myrsinaceae Fruit 
6. Daruharidra Berberis aristata DC. Berberidaceae Bark  
7. Chitraka Plumbago zeylanica Linn. Plumbaginaceae Root 
8. Kustha Saussurea lappa CB. Clarke. Compositae Root 
9. Haridra Curcuma longa Linn. Zingeberaceae Rhizome 
10. Haritaki Terminalia chebula Retz. Combretaceae Pericarp  
11. Bibhitaki Terminalia bellirica Combretaceae  Pericarp  
12. Amalaki Embelica officinalis Gaertn. Euphobiaceae Pericarp  
13 Danti Baliospermum montanum Euphobiaceae Root 
14. Chavya Piper retrofactum Vahl. Piperaceae Root  
15. Kalingaka Holarrhena antidysenterica Wall. Apocynaceae Seed 
16. Pippali Piper longum Linn. Piperaceae Fruit 
17. Pippalimool Piper longum Linn. Piperaceae Root  
18. Mandura Bhasma Iron oxide Calx Dhatu Varga - 
19. Go-Mutra Cow Urine - - 
Analytical Study of Trial Drug 
The trial drug sample was subjected to various 
physiochemical analytical tests to evaluate the 
standards of drug.  
Analytical test reports of the trial drug Guda haritaki 
are as follows. 
Nature of preparation: Viscous liquid  
Colour: Dark brow  
Odour: Characteristics 
Taste: Sweet and astringent 
pH: 3.65 
Refractive index: 1.505 at 240c  
Predicted shelf life (ASLT): 3 years from 
manufacturing date 
The sample exhibited positive test for tannins. 
Analytical test reports of the trial drug Punarnava 
mandura are as follows 
Nature of preparation: Vati 
Colour: Blackish Brown  
Odour: Characteristic 
Taste: Slightly bitt 
Ash value: 56.348% 
Acid insoluble ash: 5.642% 
Predicted shelf life (ASLT): 6 years from 
manufacturing date 
Microbial contamination tests, heavy metal residues, 
and pesticide residues were within the normal limits. 
The sample exhibited positive test for iron. 
Schedule of Treatment 
Deworming was done before drug therapy in 
suspected cases. 
The registered study subjects were randomly divided 
in three groups.  
Group A: 15 Patients – Guda haritaki 500mg/kg/day, 
before meal (divided in two doses) 
Group B: 10 patients – Punarnava mandura 500 mg 
twice a day, before meal  
Group C: 10 Patients – Each patient was managed 
with both drugs in similar doses. 
Duration of treatment: 4 weeks. 
Diet: Normal diet was advised to all the cases 
according to age. 
Follow-ups were done every 2 weeks. 
Follow-up feedback (responses on treatment) were 
taken after 6weeks  
Assessment Criteria 
The results of the clinical study were assessed 
on the basis of observations of clinical features and 
laboratory findings. The following parameters were 
mainly adopted for assessing the response of the 
treatment. 
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Clinical Assessment: Vaivarnata (pallor), Daurbalya 
(weakness), Shrama (fatigue), Aruchi (anorexia), 
Kopana or Adhira (irritability), Shwasa (dyspnea), 
Hridayaspandana (palpitation) etc clinical findings 
were assessed before, during, and after the 
treatment. 
Panduta (Twacha, Nakha, Netra, Jihwa, 
Hastapadana (Pallor) 
Absent : 0 
Present at 1 sites  : 1 
Present at 2 sites : 2 
Present at 3 sites : 3 
Present at all sites : 4 
Daurbalya (Weakness) 
Not present  : 0 
After heavy work, relieved soon and 
tolerable 
: 1 
After moderate work, relieved soon 
and tolerable 
: 2 
After little work, relieved later and 
tolerable 
: 3 
After little work, relieved later and 
beyond tolerable 
: 4 
Hridaspandanama (Palpitation)  
Not present  : 0 
After heavy work, relieved soon and 
tolerable 
: 1 
After moderate work, relieved soon 
and tolerable 
: 2 
After little work, relieved later and 
tolerable 
: 3 
After little work, relieved later and 
beyond tolerable 
: 4 
Shunakshikuta (Periorbital edema)  
Absent : 0 
Mild : 1 
Moderate : 2 
Severe : 3 
Aruchi (Anorexia)    
Absent : 0 
Present  : 1 
Pindikodwestana (Calf muscle pain) 
Absent : 0 
After heavy work : 1 
After moderate work : 2 
Without work  : 3 
Ayasaja swasa (Shortness of breath)   
No : 0 
Mild : 1 
Moderate : 2 
Severe  : 3 
Very severe : 4 
Shirshoola (Headache) 
No : 0 
Mild : 1 
Moderate : 2 
Severe  : 3 
Very severe : 4 
Bhrama (Dizziness)  
No : 0 
Mild : 1 
Moderate : 2 
Severe  : 3 
Mukha paka (Angular stomatitis)  
Not present : 0 
Present occasionally : 1 
Present mostly  : 2 
Karnakshweda (Tinnitus) 
Not present : 0 
Present occasionally : 1 
Present mostly  ; 2 
Pica  
Not present : 0 
Present  : 1 
Disturbed sleep  
Not present : 0 
Present  : 1 
Laboratory Investigations 
1. Hb (Haemoglobin) 
2. Total RBC (Red Blood Cell) 
3. Total WBC (White Blood Cell) 
4. PCV (Pack Cell Volume) 
5. MCV (Mean Corpuscular Volume) 
6. MCH (Mean Corpuscular Haemoglobin) 
7. MCHC (Mean Corpuscular Haemoglobin 
Concentration) 
8. ESR (Erythrocyte Sedimentation Rate) 
Biochemical examination: Blood sugar, SGOT, 
SGPT, Blood Urea, Sr. Creatinine, Sr. Ferritin 
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Criteria of Assessing Overall Effect of Therapy 
The assessment of overall effect was done after 
completion of treatment i.e. after 4 weeks.  
Criteria of Assessing Overall Effect of Therapy 
The assessment of overall effect was done after 
completion of treatment i.e. after 4 weeks.  
Table 3: Criteria of assessment of effect of therapy 
Cure 100% in the subjective parameter 
Markedly Improvement >75% improvement in the subjective parameter 
Moderate Improvement 50 to 74% improvement in the subjective parameter 
Mild Improvement 25 to 49% improvement in the subjective parameter 
Unchanged  <25% improvement in the subjective parameter 
Statistical Analysis: The result obtained from the study were subjected to statistical analysis in term of mean, 
standard deviation (S.D.) and standard error (S.E.), t value, p value and f values in paired ‘t’ test and Anova test 
was carried out at p> 0.05, p< 0.05, p< 0.01, p< 0.001 and a significant level for each set of data. The obtained 
results were interpretated as Insignificant (p> 0.05), Significant (p< 0.05, p<0.01) and highly significant (p< 
0.001).  
Observations and Results 
In the present study 60 children were screened, out of which 35 children were registered and 29 patients has 
completed the trial. 6 patients were dropout from the trial. 
Figure 1: Observations 
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 Majority of patients (62.85%) were in the age group of 10-13 years. Maximum number of patients i.e., 
65.71% were female followed by 34.29% were male. Most of the registered subjects were educated up to 
primary (54.28%) and 35.71% patients were studying in high school. The maximum numbers of patients 
(48.50%) were from middle class, followed by (42.85%) patients of lower middle class and patients of upper 
class were least in number (8.65%). In present study 68.60% patients were dwelling in rural area followed by 
31.40% in semi-urban area and none of the patient was from urban area. This study shows (52.17%) of 
patients were of menstruating age group and (47.83%) patients were of non menstruating age group. A total of 
68.60% of patients were vegetarian and 31.40% patients were mixed types and none of the patients were non-
vegetarian. Maximum number (57.15%) patients were of Pittakapha prakriti type followed by 28.55% were 
Vatapitta prakriti type and 14.25% were Vatakapha prakriti. In this study maximum (65.71%) patients of iron 
deficiency anemia had regular bowel habit followed by 37.29% patients having irregular bowel habit.  
Figure 2: Presentation of symtomatological data 
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DISCUSSION  
Table 4: Effect of therapy (A) 
Subjective 
Parameters 
Mean score % Relief 
(Improvement) 
SSC MSC   F 
value  
P 
value  
Result 
Dfa  Dfb  Dfc  Dfa  Dfb  Dfc  
n = 10   n = 9  n = 10  n = 10   n = 9  n = 10  
Panduta  1.000  1.111  1.300  58.82  67  65  7.448  0.266  1.128  0.347  IS  
Daurbalya  0.900  0.778  1.400  40  58.28  69.6  6.966  0.249  5.013  0.019  S  
Bhrama  0.500  0.556  0.800  62.50  71.4  88.9  10.828  0.387  0.745  0.489  IS  
Shirshoola  0.700  0.444  1.000  53.84  50  71.42  7.793  0.278  2.902  0.082  IS  
Hridspandana  0.500  0.889  1.100  55.57  61.5  78.6  14.138  0.505  2.559  0.107  S  
Ayasaja shwasa  0.800  0.556  1.300  66.67  55.6  76.5  14.69  0.525  3.075  0.072  IS  
Pica  0.200  0.222  0.100  66.67  100  50  4.138  0.148  0.224  0.802  IS  
Mukhapaka  0.400  0.333  0.800  66.67  75  89  13.241  0.473  1.1358  0.284  IS  
Aruchi  0.800  0.667  0.800  80  100  80  5.310  0.190  0.386  0.685  IS  
Karnakshweda  0.100  0.222  0.300  50  66.7  100  4.759  0.170  0.630  0.545  IS  
Brittle nails  0.100  0.222  0.100  25  100  20  3.448  0.123  0.327  0.726  IS  
Disturbed sleep  0.500  0.556  0.600  71.42  71  86  7.172  0.256  0.112  0.894  IS  
Pindikodwesta  0.300  0.788  1.000  60  64  77  12.207  0.436  4.621  0.025  S  
Shunakshikuta  0.100  0.333  0.300  100  50  100  5.310  0.190  0.889  0.425  IS  
In the present study 58.82% improvement in 
Panduta was observed with Guda haritaki, 65% with 
Punarnava mandura and 67 % when both drugs were 
given together. Result was found statistically highly 
significant in all three groups (p<0.001). Guda 
haritaki contains Haritaki which is Yakritutejaka [7] 
hence, potential to regularize Moola of Raktavaha 
srotasa which ultimately helps in improving the 
process of Rakta formation. It also contains Guda and 
Madhu which are rich source of iron. It also pacifies 
vitiated Pitta dosha, thus overcomes Panduta. 
Intergroup comparison on Panduta then was 
statistically insignificant (P value=0.347, F value 
=1.128).  
Daurbalya was present in 97 % patients just 
like previous studies.[17] It is caused due to 
Ojaskshaya, Dhatu kshaya and Raktalpata.[8] 
Statistically highly significant improvement (p value 
<0.001) in Daurbalya was observed in three groups 
with 40%, 58.28% and 69.60% improvement in 
group A, B and C respectively. Punarnava mandura 
contains Triphala which has Rasayana property while 
Guda haritaki contains Haritaki which also has 
Rasayana Property so it is effective in decreasing 
Daurbalyata[8]. It was observed that there was 
statistically significant difference (p=0.019) among 
the groups. However therapy given in group-B had 
little upper edge over group-A and group-C was 
found most effective in managing Daurbalya.  
Hridaspandana or palpitation occurs as a 
compensatory mechanism in the body, as due to lack 
of RBC in blood oxygen transport has to be 
compensated by increased blood flow to the 
peripheral circulation. This can be done by increased 
heart rate by increasing the pumping blood[9]. Thus 
palpitation felt in the patients. It can be found due to 
Vata Vridhi. Among the 51.40% cases in which the 
symptom was observed, 55.57% relief was found in 
group A, 61.5% relief was found in group B and 
78.6% relief was found in group C. It is significant 
result in all groups. There was significant difference 
(P=0.107) among three groups. However therapy 
given in group-B had little upper edge over group-A 
and group-C proved best in managing Hrida-
spandana. Guda Haritaki contains Haritaki, which 
possess Tridoshashamaka property especially 
Vatashamaka along with Raktavardhaka properties 
of Madhu and Guda. So it might be the reason in 
decreasing Hridaspandana. Punarnava Mandura 
contains Mandura which is Raktavardhaka so helps to 
increase oxygen carrying capacity by improving 
haemoglobin thus workload on heart decreases. 
Shunakshikuta was observed in only 28% 
patients. In group A and C 80% relief was observed. 
Such type of result may be due to Guda haritaki and 
Punarnava mandura which contain sufficient amount 
of iron and have potential to increase haemoglobin. A 
statistically insignificant improvement in 
Shunakshikuta was observed in all three groups i.e. 
group A (0.343), group B (0.081) and group C 
(0.081). Percentage improvement on Shunakshikuta 
in patients of group A, group B and group C was 80%, 
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50% and 80% respectively. The inter group 
comparison revealed that there was insignificant 
difference (P=0.425) among three groups. However 
therapy given in group-A and group-C proved equally 
affected but group-B proved least effective in 
managing Shunakshikuta. 
 Dyspnoea on exertion or Ayasaja shwasa in 
Pandu is due to Raktalpata which results in 
respiratory system to work quickly so as to provide 
rapid blood flow to body tissues.[10] Shwasa was 
found in 91.40% patients. Relief in Shwasa was 
maximum in group C i.e. 76.50% and in group A it 
was 66.67%. Punarnava Mandura using patients 
were relieved about 55%. There was insignificant 
difference (P=0.072) among three groups. Guda 
Haritaki contains Guda and Haritaki they both have 
Deepana, Pachana properties thus helps to improve 
Agni and ultimately helps in providing proper 
nourishment to the body. Haritaki is Srotoshodhaka 
so it opens the channels in intestine so that nutrients 
are absorbed properly. While Punarnava mandura 
contains Pippali, Pippalimula, Chitraka and Shunthi 
etc. which are known drug for their Shwasahara and 
Kaphavata nashana properties, It get quickly 
absorbed in Shrotasa. Both the drugs also increased 
Hb levels due to Madhu, Guda and Lauha Bhasma so 
oxygen carrying capacity of RBCs may be increased. 
Aruchi was found in 92.50% registered 
patients. In Pandu roga, Rasavaha srotodushti is seen 
and Aruchi has been mentioned as Rasavaha srotasa 
dushti lakshana by Acharya Charaka. A statistically 
highly significant (p<0.001) improvement in Aruchi 
was observed in group A and group C while 
significant result in group B (P=0.004). Percentage 
improvement on Aruchi in patients of group A, group 
B and group C was 100%, 80% and 100% 
respectively. However therapy given in group-A and 
group-C had equal improvement but group-B proved 
best in managing Aruchi. 
 Pindikodwestana was seen in 61% of patients. 
A statistically significant improvement in 
Pindikodwestana was observed in group B (P=0.008) 
and group C (P=0.001). Percentage improvement on 
Pindikodwestana in patients of group A, group B and 
group C was 60%, 64% and 77% respectively. The 
inter group comparison revealed that there was 
significant difference (P=0.025) among three groups. 
However therapy given in group-B had little upper 
edge over group-A and group-C proved best in 
managing Pindikodwestana. In both formulations, 
drugs contain Deepana and Pachana property which 
helps in Ama paachana. Lactic acid can be considered 
as Ama. So that patient gets relieved from leg cramps. 
Haritaki is Srotoshodhaka and Rasayana so gives 
strength to the muscles. Punarnava Mandura have 
Triphala which is Rasayana thus gives strength to 
muscles. 
 Disturbed sleep was seen in 68.5% patients. A 
statistically significant improvement in disturbed 
sleep was observed in all three groups i.e. group A 
(0.015), group B (0.013) and group C (0.005) with 
71.42%, 71% and 86% improvement respectively. An 
insignificant difference (P=0.894) among three 
groups where therapy given in group-A had little 
upper edge over group-B and group-C proved best in 
managing disturbed sleep.  
 Headache was present in 71.10% patients. 
Previous researchers also reported the similar 
observations.[17] A statistically highly significant 
(p<0.001) improvement in Shirshoola was observed 
in groups i.e. group C while significant improvement 
was observed in group B (P=0.001) and group A 
(P=0.035). Percentage improvement on Shirshoola 
in patients of group A, group B and group C was 
50%, 53.84% and 71.42% respectively. The inter 
group comparison revealed that there was 
insignificant difference (P=0.082) among three 
groups. However therapy given in group-A had little 
upper edge over group-B and group-C proved best 
in managing Shirshoola. 
  Several studies showed that the milder form 
of anaemia is silent i.e. without symptoms, while in 
the severe cases it is associated with fatigue, 
weakness, dizziness and drowsiness.[14] This 
symptom is found in 45.70% patients only. 62.50 % 
relief in group A, 71.4% relief in group C while 88.9 
% relief was found in group C. it was statistically 
significant result. Comparative result (F Value0.745 
and p value 0.489) among groups is found 
statistically insignificant. In present study 
Mukhapaaka was found in 45% registered patients. It 
is a feature of long standing anaemia. Angular 
cheilitis is an inflammatory condition characterized 
by erosive inflammation at one or both angles of the 
mouth. It typically presents as erythema, scaling, 
fissuring, and ulceration. Effect of therapy was found 
significant in group A (p value 0.037), insignificant in 
group B (p value 0.195) and significant in group C 
with p value 0.011. 66.67% relief in group A, 75 % 
relief in group C while 89 % relief was found in group 
C. In comparison among the groups result was 
statistically insignificant with p value 0.284 and f 
value 1.1358. A wide variety of factors, including 
nutritional deficiencies, local and systemic factors, 
and drug side effects, may produce cheilitis/ 
glossitis.[11-12] Ringing in ears was found only in 28.50 
% patients.  
 Iron is required for normal functioning of the 
auditory system. The loss of hemoglobin in red blood 
cells which carry oxygen to the tissues in the body. 
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Iron deficiency can disrupt the workings of cells and 
even kill them leading to hearing loss if that happens 
to hair cells in the inner ear[13] Iron deficiency results 
in the degradation of lipid saturase and desaturase, 
impairing energy production, and consequently, 
myelin production. Damage to the myelin 
surrounding the auditory nerve impairs conduction 
velocity resulting in noise induced hearing loss.[15]A 
statistically insignificant (p>0.1) improvement in 
Karnakshweda was observed in all three groups i.e. 
group A (P=0.343), group B (0.169) and group C 
(P=0.081). Percentage improvement on Karna-
kshweda in patients of group A, group B and group C 
was 50%, 66.7% and 81% respectively. The inter 
group comparison revealed that there was 
insignificant difference (P=0.545) among three 
groups. However therapy given in group-A had little 
upper edge over group-B and group-C proved best in 
managing Karnakshweda. 
 Pica is not a cause of iron deficiency anemia; 
pica is a symptom of iron deficiency anemia. Pica 
decreases the absorption of dietary iron. Other 
studies also showed that mean hemoglobin and 
plasma Fe levels were significantly lower in children 
with pica compared to controls.[16] Pica was present 
in 22.8% children. A statistically insignificant 
improvement in pica was observed in all three 
groups i.e. group A (P=0.168), group B (P=0.169) and 
group C (P=0.343) however Percentage improvement 
on pica in patients of group A, group B and group C 
was 66.67%, 71% and 76% respectively. The inter 
group comparison revealed that there was 
insignificant difference (P=0.802) among three 
groups. However therapy given in group-B had little 
upper edge over group-A and group-C proved best in 
managing pica. 
 A statistically highly significant (p<0.001) 
improvement in haemoglobin value was observed in 
all three groups with 9.16%,10.16% and 19.19% 
Percentage improvement on haemoglobin value in 
patients of group A, group B and group C was 
respectively. The inter group comparison revealed 
that there was statistically highly significant 
difference (P<0.001) among three groups. However 
therapy given in group-B had little upper edge over 
group-A and group-C proved best in managing 
haemoglobin concentration in blood. 
Table 5: Effect of therapy (B) 
Objective 
parameters  
Mean score  % change  SSC  MSC   F 
value  
P 
value  
Result  
Dfa  Dfb  Dfc  Dfa  Dfb  Dfc  
n = 10   n = 9  n = 10  n = 10   n = 9  n = 10  
HB  0.930  1.033  1.864  9.16  10.16  19.19  11.304  0.404  13.838  <0.001  HS  
Sr.Ferritin  0.798  0.243  1.392  4.20  0.69  6.80  102.133  3.648  1.114  0.351  IS  
MCV  2.825  3.272  4.023  3.76  4.43  5.47  386.93  13.89   2.510  0.111  IS  
MCH  0.400  1.156  0.180  01.51  4.37  0.65  88.130  3.148  0.649  0.535  IS  
MCHC  0.337  1.75  0.860  0.96  5.03  2.45  62.94  2.248  2.570  0.106  IS  
 A statistically insignificant change in Sr. Ferritin was observed in all three groups i.e. group B (P=0.127), 
group A (P=0.804) and group C (P=0.003). Percentage improvement on Sr. Ferritin in patients of group A, 
group B and group C was 0.69%, 4.2% and 6.80% respectively. The inter group comparison revealed that there 
was insignificant difference (P=0.351) among three groups. A statistically significant improvement in MCV, 
MCH and MCHC was observed in all three groups. The inter group comparison revealed that there was 
insignificant difference among three groups. Rests of investigations (TLC, DLC, ESR etc.) were under normal 
range before and after the therapy. 
Table 6: Overall effect of therapy 
Groups  Cured  Marked 
improvement  
Moderately 
improvement  
Mildly 
improvement  
Unchanged  Total  
Gr. A  00  01(10%)  08(80%)  01(10%)  00  10  
Gr. B  00  03(33.33%)  6(66.67)  00  00  09  
Gr. C  00  06(60%)  4(40%)  00  00  10  
Total  00  10(34.48%)  18(62.06%)  01(3.44%)  00  29  
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Figure 3: Overall effect of therapy 
 
After treatment, the trial Group A, one patient 
(10%) showed marked improvement, 8 patients 
(80%) showed moderate improvement and 01 
patient (10%) showed mild improvement and none 
of the patient remains unchanged. In group B, three 
patients (33.33%) showed marked improvement and 
6 patients (66.67%) showed moderate improvement 
whereas none of the patient remains unchanged. In 
group C, 6 patients (60%) showed marked 
improvement and 4 patients (40%) showed 
moderate improvement and none of the patient 
remains unchanged. The study shows that 
combination Punarnava mandura and Guda haritaki 
can be considered to be most effective whereas 
Punarnava mandura is more effective than Guda 
haritaki for the correction of microcytic and 
hypochromic anemia. All the patients were examined 
biweekly for evaluation of any adverse drug reaction. 
The drugs were tolerated well and not a single 
patient exhibited any adverse symptom. 
 Ingredients of Guda haritaki have Madhura 
and Kashaya rasa and predominance of Laghu Guna. 
Madhura and Kashaya rasas perform Pitta shamaka 
function which breaks the pathogenesis of Pandu 
roga prior to Hridaprapti of vitiated Pitta dosha. The 
ingredients like Haritaki and Madhu help in Kostha 
shodhana which leads to the expulsion of vitiated 
Pitta from GI tract. Vipaka of most of the ingredients 
of the formulations is Madhura, which help in 
formation of optimum quantity of Dhatus, nourishes 
Manna and Indriyas and also alleviate vitiated Vata 
Dosha. Madhura Vipaka also increases the vital 
strength. Guda haritaki contains Deepana, Pachana 
dravya which regularize gastric Ph through its Ushna 
Veerya which also helps in clearing Srotorodha. 
Improvement in digestion and metabolism leads to 
proper Dhatu Poshana. Guda is a natural source of 
iron. It has got Raktakrita property. The iron fraction 
of Guda along with Madhu provides optimum amount 
of iron which is required for normal erythropoiesis. 
Madhu is a source of vitamin C which helps in 
absorption of iron. 
 Analysis of pharmacodynamic properties of 
Punarnava Mandura reveals that maximum 
ingredients of the formulation have Katu and Tikta 
Rasa and predominance of Laghu Guna. Tikta and 
Katu Rasas perform Agnideepana function which 
increase the metabolism and reduces the formation 
of Ama. Vipaka of most of the ingredients of the 
formulations is Katu and Madhura. Madhura vipaka 
help in formation of optimum quantity of Dhatus, 
nourishes  Manna and Indriyas and also alleviate 
vitiated Vata Dosha. Madhura vipaka also increases 
the vital strength. Katu vipaka helps in regularization 
of metabolism. The ingredients like Danti and Trivrita 
help in Kostha shodhana which leads to vitiated Pitta 
nishkasana from GI tract. This activity is very 
essential in breaking the pathogenesis of Pandu. The 
Krimihara property of different ingredient of the 
formulation like Vibhitaki, Haridra, Vidanga, Maricha, 
Musta etc may be beneficial in cases of Mritika 
bhakshana janya Pandu and worm infestation. 
Punarnava Mandura contains Deepana, Pachana 
dravyas, which regularize gastric Ph through their 
Ushna and Tikshna Guna and Ushna Veerya helps in 
clearing Srotorodha. So improvement in metabolism 
and digestion leads to proper Dhatu Poshana. 
Mandura Bhasma is a natural source of iron. It has got 
Raktavriddhikara property. The iron fraction of 
Mandura provides optimum amount of iron which is 
required for normal erythropoiesis. Amalaki is 
richest source of vitamin C which helps in absorption 
of iron. Triphala is Rasayana, Trikatu is Deepana, and 
Trimada has Pachana properties. Activity of 
Punarnava Mandura gets potentiated due to presence 
of Gomutra, which has therapeutic attribute like- 
Panduhara, Mutrala, Shophhara, Krimihara and 
Deepana. Punarnava mandura is thus capable of 
executing Samprapti Vighatana of Pandu at various 
levels. Apart from this it also possess Rasayana 
property and has got Vyadhi pratyenika effect on 
Pandu.  
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CONCLUSIONS 
 Prevalence of Anaemia among school going 
children in Distt. Kangra was observed to the tune of 
69%.[18] Important determinates of anaemia 
observed in survey study were adolescent age, female 
gender, excessive menstruation, lower socio-
economic status, low birth weight , caesarean section 
delivery, vegetarian diet, not having history of 
exclusive breast feeding and dewormification. In 
adolescent age group iron deficiency Anaemia is 
comparatively more common among females. 
Therapy given in group-C where patients were 
managed with Guda Haritaki as well as Punarnava 
Mandura proved best in management of Pandu in 
comparison to group A and B where patients were 
managed with Guda Haritaki and Punarnava Mandura 
respectively. No untowards effects were observed in 
all the three groups during the entire trial period.  
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